CA
PPH icon

Continuum Advisory’s VanEck Pharmaceutical ETF PPH Stock Holding History

Continuum Advisory’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-610
Closed -$55.6K – 1260
2025
Q1 		$55.6K Hold
610
– – 0.01% 647
2024
Q4 		$52.7K Buy
610
+3
+0.5% +$271 0.01% 651
2024
Q3 		$53.6K Buy
607
+5
+0.8% +$475 0.01% 642
2024
Q2 		$55.1K Hold
602
– – 0.01% 597
2024
Q1 		$53.8K Buy
+602
New +$52.7K 0.01% 588
2023
Q4 		– Sell
-2,906
Closed -$232K – 482
2023
Q3 		$232K Buy
2,906
+101
+4% +$8.14K 0.04% 403
2023
Q2 		$221K Buy
2,805
+2
+0.1% +$157 0.04% 415
2023
Q1 		$218K Sell
2,803
-870
-24% -$67.1K 0.04% 398
2022
Q4 		$286K Buy
+3,673
New +$271K 0.05% 350

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Continuum Advisory's PPH Position: Q2 2025 in Review

Continuum Advisory sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2025, closing a stake of 610 shares — an estimated $55.6K sold.

Continuum Advisory first reported a position in PPH in Q4 2022 and held it in 9 quarters. The position peaked at $286K in Q4 2022. 129 funds tracked by Wall St. Rank hold PPH as of Q2 2025.

  • Continuum Advisory reported no remaining VanEck Pharmaceutical ETF position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 610 VanEck Pharmaceutical ETF shares in Q2 2025, an estimated $55.6K.
  • Continuum Advisory first reported a position in VanEck Pharmaceutical ETF in Q4 2022 and held it in 9 quarters.
  • Continuum Advisory's VanEck Pharmaceutical ETF position peaked at $286K in Q4 2022.
  • 129 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.